-
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
30 Jan 2025 13:00 GMT
… treatment options,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “As … , which was originally developed by Eisai Co. Ltd. and was formerly …
-
JPM25, Day 2: Biogen ready to stand its ground in Alzheimer's showdown, CEO says
14 Jan 2025 21:48 GMT
… treatment last year, Biogen CEO Chris Viehbacher said his company … ago, Biogen and partner Eisai secured accelerated FDA approval for … drugs in our history,” CEO Vas Narasimhan said during the … from the killing of UnitedHealthcare CEO Brian Thompson in New …
-
Neophore Appoints Michael Shih As Chief Executive Officer
16 Dec 2024 09:33 GMT
… of Michael Shih as Chief Executive Officer (CEO) and to the … Epizyme, Forest Laboratories and Eisai.
Robert James, Chairman of … Michael Shih, newly appointed Chief Executive Officer and Board of … positions in-house at Eisai Inc., specialising in licensing …
-
NeoPhore appoints Michael Shih as CEO
31 Dec 2024 09:02 GMT
… of Michael Shih as chief executive officer (CEO) and to the board … Epizyme, Forest Laboratories and Eisai.
Robert James, chairman of … legal positions in-house at Eisai, specialising in licensing, corporate … new appointment of the CEO strengthen NeoPhore's …
-
Fujirebio And Eisai Enter Into Memorandum Of Understanding For Joint Research And Social Implementation Of Blood-Based B...
23 Dec 2024 19:52 GMT
… Group CEO: Shigekazu Takeuchi; Head Office: Minato-ku, Tokyo), and Eisai Co … ., Ltd. (Representative Corporate Officer and CEO: Haruo Naito … ; Head Office: Bunkyo-ku, Tokyo; hereinafter "Eisai …
-
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
23 Dec 2024 12:03 GMT
… Group CEO: Shigekazu Takeuchi; Head Office: Minato-ku, Tokyo), and Eisai Co … ., Ltd. (Representative Corporate Officer and CEO: Haruo Naito … ; Head Office: Bunkyo-ku, Tokyo; hereinafter "Eisai …
-
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal
19 Dec 2024 15:43 GMT
… the Alzheimer’s space, tapping Eisai’s partner BioArctic for a … and society,” the biotech’s CEO Gunilla Osswald said in a …
-
Eisai Subsidiary inks €117 M deal for schizophrenia treatment in Japan and other Asian territories
16 Dec 2024 13:09 GMT
… Pharma Co., a subsidiary of Eisai Co., have entered into a … 2024 financial statements.
Stefan Weber, CEO of Newron, commented: “We are …
-
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories
13 Dec 2024 12:47 GMT
… “EA Pharma”), a subsidiary of Eisai Co., Ltd., today announced that … 2024 financial statements.
Stefan Weber, CEO of Newron, commented: “This … Ltd. is a subsidiary of Eisai Co., Ltd. It was … year’s history of the Eisai Group and the gastrointestinal …
-
Eisai launches Alzheimer’s treatment Leqembi in Korea
28 Nov 2024 05:35 GMT
Eisai Korea announced Thursday the launch … causes,” said Ko Hong-byung, CEO of Eisai Korea. “The introduction of … mild cognitive impairment stage."
Eisai Korea is also pursuing regulatory …
About
© 1995-2025